TrialESMO open2024

Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors.

C Madeddu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.